110013 ⎘
dsDNA viruses; Details; Poxviridae; Orthopoxvirus, e.g. vaccinia virus, variola New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
USE OF DR-18 AND ONCOLYTIC VACCINIA VIRUS IN PREPARATION OF ANTI-TUMOR DRUG
#2ONCOLYTIC VIRUS SIMULTANEOUSLY EXPRESSING CD55 AND CD59
#3IMPROVED VACCINIA VIRUS VECTORS
#4COMPOSITIONS OF CD47/SIRP-ALPHA IMMUNE CHECKPOINT INHIBITORS AND USES THEREOF
#5METHODS FOR PRODUCTION OF THERAPEUTIC IMMUNE CELLS HAVING ENHANCED METABOLIC FITNESS AND COMPOSITIONS THEREOF
#6TNFSF-L Fusion Proteins and Uses Thereof
#7HUMAN METAPNEUMOVIRUS COMBINATION VACCINE
#8SYNTHETIC BIOLOGY APPROACHES TO TARGET RNA-CAPPING ENZYMES FROM VIRUSES
#9METHOD OF PRODUCING NEGATIVE-STRAND RNA VIRUS VECTOR AND PRODUCED NEGATIVE-STRAND RNA VIRUS VECTOR
#10SELF-AMPLIFYING MESSENGER RNA
#11COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY
#12VIRUSES ENGINEERED TO PROMOTE THANOTRANSMISSION AND THEIR USE IN TREATING CANCER
#13ENHANCED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
#14STRAIN DIS-DERIVED RECOMBINANT VACCINIA VIRUS HAVING NOVEL INFLUENZA VIRUS-DERIVED HEMAGGLUTININ PROTEIN GENE
#15PROCESS FOR DESIGNING A RECOMBINANT POXVIRUS FOR A THERAPEUTIC VACCINE
#16BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING
#17Immuno-Oncolytic Therapies
#18TUMOR-TARGETING PROTEIN OR FRAGMENT THEREOF, ANTIBODY BINDING THERETO AND USE THEREOF
#19USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS
#20M2-DEFECTIVE POXVIRUS
#21MODIFIED ORTHOPOXVIRUS VECTORS
#22Modified Extracellular Enveloped Virus
#23MUTANT VACCINIA VIRUSES AND USE THEREOF
#24Integral membrane protein display on poxvirus extracellular enveloped virions
#25INHIBITION OF INNATE IMMUNE RESPONSE
#26Compositions and methods for targeted cytokine delivery
#27Compositions and methods for modulating inflammatory responses
#28Isolated Recombinant Oncolytic Poxvirus, Pharmaceutical Composition, and Use Thereof in Treatment of Tumors and/or Cancer
#29Recombinant vaccinia virus and methods of use thereof
#30Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#31Integral membrane protein display on poxvirus extracellular enveloped virions
#32VIRAL VECTOR MANUFACTURE
#33Stable virus-containing composition
#34Enhanced systems for cell-mediated oncolytic viral therapy
#35Poxvirus-recombinants, compositions containing such recombinants, uses thereof, and methods of making and using the same
#36Non-genetic modification of enveloped viruses
#37Vaccinia virus vectors related to MVA with extensive genomic symmetries
#38Integral membrane protein display on poxvirus extracellular enveloped virions
#39Oncolytic vaccinia virus mutants and using same for cancer treatment
#40Integral membrane protein display on poxvirus extracellular enveloped virions
#41Compositions and methods for targeted cytokine delivery
#42Method of treatment using oncolytic viruses
#43Inhibition of innate immune response
#44Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#45PR13.5 promoter for robust T-cell and antibody responses
#46Whole expressed cell as antigen carrier, and use thereof in preparing vaccine or diagnostic agent, and screening monoclonal antibodies
#47Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
#48Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit
#49Virus-based expression vectors and uses thereof
#50TAT-CrmA anti-apoptotic fusion proteins
#51Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
#52Monoclonal antibodies against orthopoxviruses
#53Compositions and methods for immunodominant antigens
#54BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING
#55Viral vector manufacture
#56Compositions and methods for immunodominant antigens of
#57Immunoregulatory peptides and methods of use
#58Immuno-oncolytic therapies
#59Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunits
#60Fusion polypeptides and vaccines
#61Pr13.5 promoter for robust T-cell and antibody responses
#62Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#63Poxviral vectors for low antibody response after a first priming immunization
#64Compositions and methods for immunodominant antigens of
#65Inhibition of innate immune response
#66Vaccinia virus polypeptides
#67Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
#68Anthrax and small pox replikins and methods of use
#69Vaccinia virus polypeptides
#70Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
#71Poxviral oncolytic vectors
#72Methods and compositions for poxvirus A35R protein
#73Monoclonal antibodies against Orthopoxviruses
#74Modulation of immune responses by the poxviral K4 protein
#75Immunoregulatory peptides and methods of use
#76Immunoregulatory peptides and methods of use
#77Immunoregulatory peptides and methods of use
#78Compositions and methods for immunodominant antigens of
#79Method and peptide for regulating cellular activity
#80POXVIRAL ONCOLYTIC VECTORS
#81Methods and Compositions for Poxvirus A35R Protein
#82IMMORTALIZED AVIAN CELL LINES FOR VIRUS PRODUCTION
#83RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRAL GENOME
#84Compositions and methods for immunodominant antigens of
#85Recombinant poxvirus expressing homologous genes inserted
#86Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#87VACCINIA VIRUS POLYPEPTIDES
#88Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#89Method and peptide for regulating cellular activity
#90Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
#91Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
#92Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs)
#93Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)
#94Anti-apoptotic fusion proteins for reducing myocardial infarction size
#95Method for the production of human immunodeficiency virus (HIV) proteins utilizing modified vaccinia virus ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)
#96Expression system
#97Vaccinia virus protein A46 peptide and use thereof
#98Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#99Intergenic regions as insertion sites in the genome of modified vaccinia virus Ankara (MVA)
#100Compositions and methods for immunodominant antigens of
#101Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#102Monoclonal antibodies against orthopoxviruses
#103Anthrax and small Pox replikins and methods of use
#104Use of mTOR inhibitors to enhance T cell immune responses
#105Poxviral oncolytic vectors
#106RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRAL GENOME
#107RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRUS GENOME
#108Poxviral oncolytic vectors
#109Interferon antagonists, antibodies thereto and associated methods of use
#110Immunoregulatory peptides and methods of use
#111Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#112Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#113System and method for identifying complex patterns of amino acids
#114REPLIKINS AND METHODS OF IDENTIFYING REPLIKIN-CONTAINING SEQUENCES
#115Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
#116REPLIKIN PEPTIDES AND ANTIBODIES THEREFOR
#117ANTI-VIRAL METHODS AND COMPOSITIONS
#118Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
#119Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
#120RECOMBINANT POXVIRUS EXPRESSING HOMOLOGOUS GENES INSERTED INTO THE POXVIRAL GENOME
#121Compositions and methods for immunodominant antigens
#122ADJUVANTED VACCINE
#123Compositions, methods and kits relating to poxvirus subunit vaccines
#124Vaccinia Virus Strains
#125Method and peptide for regulating cellular activity
#126Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#127Compositions and methods for immunodominant antigens of
#128IMMUNOGENIC VACCINIA PEPTIDES AND METHODS OF USING SAME
#129REPLIKIN PEPTIDES IN RAPID REPLICATION OF GLIOMA CELLS AND IN INFLUENZA EPIDEMICS
#130Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#131Vaccinia virus strains
#132VACCINIA VIRUS HOST RANGE GENES TO INCREASE THE TITER OF AVIPOXVIRUSES
#133Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#134Monoclonal antibodies against orthopoxviruses
#135Methods and compositions for poxvirus lacking A35R protein
#136Orthopoxvirus vectors, genes and products thereof
#137REPLIKIN PEPTIDES AND ANTIBODIES THEREFORE
#138Systems and methods for viral therapy
#139IMMUNOMODULATORY COMPOSITIONS AND USES THEREFOR
#140Anti-Inflammatory Proteins and Improved Vaccines
#141Chemokine binding activity of viral TNF receptors and related proteins
#142Methods for attenuating virus strains for diagnostic and therapeutic uses
#143DNA immunogenic composition comprising a full-length modified poxvirus L1R gene fused to a tPA leader sequence
#144Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
#145Novel Therapeutic Use of Viral Inflammation Modulatory Protein in Blocking Xenograft Rejection
#146Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#147Isolated recombinant vaccinia virus complement control protein (hrVCP) polypeptide
#148Semaphorin Gene Family
#149Replikins and methods of identifying replikin-containing sequences
#150Immortalized avian cell lines for virus production
#151Immunodeficiency recombinant poxvirus
#152Expression system
#153Composition and Method for Inducing Protective Vaccine Response Using SDF-1
#154Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
#155Peptide originating from vaccinia virus
#156Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
#157Treatment of spinal cord injury
#158Anthrax and small pox replikins and methods of use
#159Composition and method for inducing protective vaccine response
#160Vaccinia virus expression vector for selective replication in a tumor cell and introduction of exogenous nucleotide sequence into a tumor cell
#161Immunomodulatory compositions and uses therefor
#162Method and peptide for regulating cellular activity
#163Treatment of rheumatic diseases
#164Replikin peptides in rapid replication of glioma cells and in influenza epidemics
#165Mutants of vaccinia virus as oncolytic agents
#166Semaphorin gene family
#167Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
#168MCV MC160 compositions and methods
#169Vaccinia virus nucleic acids, polypeptides and immunogenic compositions
#170Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
#171Recombinant poxvirus expressing homologous genes inserted into the foxviral genome
#172Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
#173Viral complement control proteins for eye disorders
#174Compositions and methods modulating variola and vaccinia virus
#175Compositions, methods and kits relating to poxvirus subunit vaccines
#176Isolated avian cell that expresses Vaccinia virus host range genes
#177Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
#178System and method for identifying complex patterns of amino acids
#179Method and peptide for regulating cellular activity
#180Use of vaccinia virus deleted for the E3L gene as a vaccine vector
#181Method of generating recombinant MVA
#182Orthopoxvirus vectors, genes and products thereof
#183Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
#184Viral CD30 polypeptide
#185Poxvirus with targeted infection specificity
#186Viral proteins capable of binding LAR
#187Orthopoxvirus vectors, genes and products thereof
#188Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
#189Compositions and methods modulating variola and vaccinia virus
#190Materials and methods for delivery and expression of heterologous DNA in vertebrate cells